Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

(2020) Rajat Bannerji et al.   BLOOD

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

(2020) Pieternella Lugtenburg et al.   BLOOD

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

(2020) Stephen J Schuster et al.   BLOOD

Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

(2020) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

(2020) Joseph Kauer et al.   Journal for ImmunoTherapy of Cancer

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

(2020) Luke Coyle et al.   LEUKEMIA & LYMPHOMA

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

(2020) Paolo Strati et al.   Blood Advances

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells

(2019) Philipp Karschnia et al.   BLOOD

Tumour flare reaction in cancer treatments

(2019) Amina Taleb B.   ANTI-CANCER DRUGS

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

(2019) Chi-Chung Li et al.   BLOOD

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

(2019) Martin Hutchings et al.   BLOOD

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

(2019) Ramesh Baliga et al.   BLOOD

Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

(2019) Ibrahim Yakoub-Agha et al.   HAEMATOLOGICA

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

(2019) Rebecca A. Gardner et al.   BLOOD

Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies

(2018) Glen Giese et al.   BIOTECHNOLOGY PROGRESS

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

(2018) Marina Bacac et al.   CLINICAL CANCER RESEARCH

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

(2018) David Porter et al.   Journal of Hematology & Oncology

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

(2016) A. Viardot et al.   BLOOD

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

(2016) Bruce D. Cheson et al.   BLOOD

Immunotherapeutic implications of IL-6 blockade for cytokine storm

(2016) Toshio Tanaka et al.   Immunotherapy

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

(2016) Fang Chen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

(2016) M Ruella et al.   LEUKEMIA

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

(2010) Asher Chanan-Khan et al.   CANCER

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH